The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These innovative therapies represent a https://miriamluja301065.jts-blog.com/37484084/glp-3-receptor-agonists-retatrutide-trizepatide